Inhibitory effects and mechanisms of Luteolin on proliferation and migration of vascular smooth muscle cells

Nutrients

Volumn 5, Issue 5, 2013, Pages 1648-1659

  Jiang, Dehua ^a   Li, Dongye ^a   Wu, Wanling ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Luteolin; Migration; Proliferation; Vascular smooth muscle cells (VSMCs)

Indexed keywords

ANGIOTENSIN II; HYDROGEN PEROXIDE; KAEMPFEROL; LUTEOLIN; PLATELET DERIVED GROWTH FACTOR BB; QUERCETIN;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL CYCLE REGULATION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PHYTOCHEMISTRY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASCULAR SMOOTH MUSCLE CELL;

EID: 84878085533     PISSN: 20726643     EISSN: None     Source Type: Journal    
DOI: 10.3390/nu5051648     Document Type: Article

References (55)

1. Doran, A.C.; Meller, N.; McNamara, C.A. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 812-819.
2. Wang, C.; Zhang, Y.; Yang, Q.; Yang, Y.; Gu, Y.; Wang, M.; Wu, K. A novel cultured tissue model of rat aorta: VSMC proliferation mechanism in relationship to atherosclerosis. Exp. Mol. Pathol. 2007, 83, 453-458.
3. Ross, J.S.; Stagliano, N.E.; Donovan, M.J.; Breitbart, R.E.; Ginsburg, G.S. Atherosclerosis and cancer: Common molecular pathways of disease development and progression. Ann. N. Y. Acad. Sci. 2001, 947, 271-292; discussion 292-293.
4. Zernecke, A.; Weber, C. Chemokines in the vascular inflammatory response of atherosclerosis. Cardiovasc. Res. 2010, 86, 192-201.
5. Boyle, EM., Jr.; Lille, S.T.; Allaire, E.; Clowes, A.W.; Verrier, E.D. Endothelial cell injury in cardiovascular surgery: Atherosclerosis. Ann. Thorac. Surg. 1997, 63, 885-894.
6. Stoneman, V.E.; Bennett, M.R. Role of apoptosis in atherosclerosis and its therapeutic implications. Clin. Sci. (Lond.) 2004, 107, 343-354.
7. Wasserman, E.J.; Shipley, N.M. Atherothrombosis in acute coronary syndromes: Mechanisms, markers, and mediators of vulnerability. Mt. Sinai J. Med. 2006, 73, 431-439.
8. Bellosta, S.; Bernini, F.; Ferri, N.; Quarato, P.; Canavesi, M.; Arnaboldi, L.; Fumagalli, R.; Paoletti, R.; Corsini, A. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998, 137, S101-S109.
9. Zeng, Y.; Song, J.X.; Shen, X.C. Herbal remedies supply a novel prospect for the treatment of atherosclerosis: A review of current mechanism studies. Phytother. Res. 2012, 26, 159-167.
10. Kelloff, G.J. Perspectives on cancer chemoprevention research and drug development. Adv. Cancer Res. 2000, 78, 199-334.
11. Manach, C.; Williamson, G.; Morand, C.; Scalbert, A.; Remesy, C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am. J. Clin. Nutr. 2005, 81, 230S-242S.
12. Loke, W.M.; Proudfoot, J.M.; Stewart, S.; McKinley, A.J.; Needs, P.W.; Kroon, P.A.; Hodgson, J.M.; Croft, K.D. Metabolic transformation has a profound effect on anti-inflammatory activity of flavonoids such as quercetin: Lack of association between antioxidant and lipoxygenase inhibitory activity. Biochem. Pharmacol. 2008, 75, 1045-1053.
13. Chen, Z.; Tu, M.; Sun, S.; Kong, S.; Wang, Y.; Ye, J.; Li, L.; Zeng, S.; Jiang, H. The exposure of luteolin is much lower than that of apigenin in oral administration of Flos Chrysanthemi extract to rats. Drug Metab. Pharmacokinet. 2012, 27, 162-168.
14. Cao, G.; Sofic, E.; Prior, R.L. Antioxidant and prooxidant behavior of flavonoids: Structure-activity relationships. Free Radic. Biol. Med. 1997, 22, 749-760.
15. Seelinger, G.; Merfort, I.; Schempp, C.M. Anti-oxidant, anti-inflammatory and anti-allergic activities of luteolin. Planta Med. 2008, 74, 1667-1677.
16. Yochum, L.; Kushi, L.H.; Meyer, K.; Folsom, A.R. Dietary flavonoid intake and risk of cardiovascular disease in postmenopausal women. Am. J. Epidemiol. 1999, 149, 943-949.
17. Middleton, E., Jr.; Kandaswami, C.; Theoharides, T.C. The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and cancer. Pharmacol. Rev. 2000, 52, 673-751.
18. Lopez-Lazaro, M. Distribution and biological activities of the flavonoid luteolin. Mini Rev. Med. Chem. 2009, 9, 31-59.
19. Lin, Y.; Shi, R.; Wang, X.; Shen, H.M. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr. Cancer Drug Targets 2008, 8, 634-646.
20. Mulvihill, E.E.; Huff, M.W. Antiatherogenic properties of flavonoids: Implications for cardiovascular health. Can. J. Cardiol. 2010, 26, 17A-21A.
21. Clarke, M.; Bennett, M. Defining the role of vascular smooth muscle cell apoptosis in atherosclerosis. Cell Cycle 2006, 5, 2329-2331.
22. Ross, J.A.; Kasum, C.M. Dietary flavonoids: Bioavailability, metabolic effects, and safety. Annu. Rev. Nutr. 2002, 22, 19-34.
23. Agullo, G.; Gamet-Payrastre, L.; Manenti, S.; Viala, C.; Remesy, C.; Chap, H.; Payrastre, B. Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: A comparison with tyrosine kinase and protein kinase C inhibition. Biochem. Pharmacol. 1997, 53, 1649-1657.
24. Lv, L.; Zhang, Y.; Kong, Q. Luteolin prevents LPS-induced TNF-α expression in cardiac myocytes through inhibiting NF-κB signaling pathway. Inflammation 2011, 34, 620-629.
25. Wang, G.; Li, W.; Lu, X.; Bao, P.; Zhao, X. Luteolin ameliorates cardiac failure in type I diabetic cardiomyopathy. J. Diabetes Complicat. 2012, 26, 259-265.
26. Kim, J.H.; Jin, Y.R.; Park, B.S.; Kim, T.J.; Kim, S.Y.; Lim, Y.; Hong, J.T.; Yoo, H.S.; Yun, Y.P. Luteolin prevents PDGF-BB-induced proliferation of vascular smooth muscle cells by inhibition of PDGF β-receptor phosphorylation. Biochem. Pharmacol. 2005, 69, 1715-1721.
27. Lang, Y.; Chen, D.; Li, D.; Zhu, M.; Xu, T.; Zhang, T.; Qian, W.; Luo, Y. Luteolin inhibited hydrogen peroxide-induced vascular smooth muscle cells proliferation and migration by suppressing the Src and Akt signalling pathways. J. Pharm. Pharmacol. 2012, 64, 597-603.
28. Zhu, M.; Chen, D.; Li, D.; Ding, H.; Zhang, T.; Xu, T.; Zhang, Y. Luteolin inhibits angiotensin II-induced human umbilical vein endothelial cell proliferation and migration through downregulation of src and akt phosphorylation. Circ. J. 2012, 77, 772-779.
29. Ando, C.; Takahashi, N.; Hirai, S.; Nishimura, K.; Lin, S.; Uemura, T.; Goto, T.; Yu, R.; Nakagami, J.; Murakami, S. et al. Luteolin, a food-derived flavonoid, suppresses adipocyte-dependent activation of macrophages by inhibiting JNK activation. FEBS Lett. 2009, 583, 3649-3654.
30. Qi, L.; Pan, H.; Li, D.; Fang, F.; Chen, D.; Sun, H. Luteolin improves contractile function and attenuates apoptosis following ischemia-reperfusion in adult rat cardiomyocytes. Eur. J. Pharmacol. 2011, 668, 201-207.
31. Sun, D.; Huang, J.; Zhang, Z.; Gao, H.; Li, J.; Shen, M.; Cao, F.; Wang, H. Luteolin limits infarct size and improves cardiac function after myocardium ischemia/reperfusion injury in diabetic rats. PLoS One 2012, 7, e33491; doi:10.1371/journal.pone.0033491.
32. Fang, F.; Li, D.; Pan, H.; Chen, D.; Qi, L.; Zhang, R.; Sun, H. Luteolin inhibits apoptosis and improves cardiomyocyte contractile function through the PI3K/Akt pathway in simulated ischemia/reperfusion. Pharmacology 2011, 88, 149-158.
33. Song, J.; Liu, K.; Yi, J.; Zhu, D.; Liu, G.; Liu, B. Luteolin inhibits lysophosphatidylcholine-induced apoptosis in endothelial cells by a calcium/mitocondrion/caspases-dependent pathway. Planta Med. 2010, 76, 433-438.
34. Muslin, A.J. MAPK signalling in cardiovascular health and disease: Molecular mechanisms and therapeutic targets. Clin. Sci. (Lond.) 2008, 115, 203-218.
35. Muto, A.; Fitzgerald, T.N.; Pimiento, J.M.; Maloney, S.P.; Teso, D.; Paszkowiak, J.J.; Westvik, T.S.; Kudo, F.A.; Nishibe, T.; Dardik, A. Smooth muscle cell signal transduction: Implications of vascular biology for vascular surgeons. J. Vasc. Surg. 2007, 45 (Suppl. A), A15-A24.
36. Fernandez-Hernando, C.; Jozsef, L.; Jenkins, D.; di Lorenzo, A.; Sessa, W.C. Absence of Akt1 reduces vascular smooth muscle cell migration and survival and induces features of plaque vulnerability and cardiac dysfunction during atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 2033-2040.
37. Stintzing, S.; Ocker, M.; Hartner, A.; Amann, K.; Barbera, L.; Neureiter, D. Differentiation patterning of vascular smooth muscle cells (VSMC) in atherosclerosis. Virchows Arch. 2009, 455, 171-185.
38. Brown, X.Q.; Bartolak-Suki, E.; Williams, C.; Walker, M.L.; Weaver, V.M.; Wong, J.Y. Effect of substrate stiffness and PDGF on the behavior of vascular smooth muscle cells: Implications for atherosclerosis. J. Cell. Physiol. 2010, 225, 115-122.
39. Perez-Vizcaino, F.; Bishop-Bailley, D.; Lodi, F.; Duarte, J.; Cogolludo, A.; Moreno, L.; Bosca, L.; Mitchell, J.A.; Warner, T.D. The flavonoid quercetin induces apoptosis and inhibits JNK activation in intimal vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 2006, 346, 919-925.
40. Kobayashi, T.; Nakata, T.; Kuzumaki, T. Effect of flavonoids on cell cycle progression in prostate cancer cells. Cancer Lett. 2002, 176, 17-23.
41. Lim, D.Y.; Jeong, Y.; Tyner, A.L.; Park, J.H. Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292, G66-G75.
42. Sriram, V.; Patterson, C. Cell cycle in vasculoproliferative diseases: Potential interventions and routes of delivery. Circulation 2001, 103, 2414-2419.
43. Wessely, R. Atherosclerosis and cell cycle: Put the brakes on! Critical role for cyclin-dependent kinase inhibitors. J. Am. Coll. Cardiol. 2010, 55, 2269-2271.
44. Zettler, M.E.; Pierce, G.N. Cell cycle proteins and atherosclerosis. Herz 2000, 25, 100-107.
45. Ferguson, J.E., III; Patterson, C. Break the cycle: The role of cell-cycle modulation in the prevention of vasculoproliferative diseases. Cell Cycle 2003, 2, 211-219.
46. Willis, A.I.; Pierre-Paul, D.; Sumpio, B.E.; Gahtan, V. Vascular smooth muscle cell migration: Current research and clinical implications. Vasc. Endovasc. Surg. 2004, 38, 11-23.
47. Lamy, S.; Bédard, V.; Labbé, D.; Sartelet, H.; Barthomeuf, C.; Gingras, D.; Béliveau, R. The dietary flavones apigenin and luteolin impair smooth muscle cell migration and VEGF expression through inhibition of PDGFR-β phosphorylation. Cancer Prev. Res. (Phila.) 2008, 1, 452-459.
48. Clarke, M.; Bennett, M. The emerging role of vascular smooth muscle cell apoptosis in atherosclerosis and plaque stability. Am. J. Nephrol. 2006, 26, 531-535.
49. Clarke, M.C.; Figg, N.; Maguire, J.J.; Davenport, A.P.; Goddard, M.; Littlewood, T.D.; Bennett, M.R. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat. Med. 2006, 12, 1075-1080.
50. Horinaka, M.; Yoshida, T.; Shiraishi, T.; Nakata, S.; Wakada, M.; Nakanishi, R.; Nishino, H.; Matsui, H.; Sakai, T. Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. Oncogene 2005, 24, 7180-7189.
51. Chang, J.; Hsu, Y.; Kuo, P.; Kuo, Y.; Chiang, L.; Lin, C. Increase of Bax/Bcl-XL ratio and arrest of cell cycle by luteolin in immortalized human hepatoma cell line. Life Sci. 2005, 76, 1883-1893.
52. Guerrero, J.A.; Lozano, M.L.; Castillo, J.; Benavente-Garcia, O.; Vicente, V.; Rivera, J. Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor. J. Thromb. Haemost. 2005, 3, 369-376.
53. Bagli, E.; Stefaniotou, M.; Morbidelli, L.; Ziche, M.; Psillas, K.; Murphy, C.; Fotsis, T. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3′-kinase activity. Cancer Res. 2004, 64, 7936-7946.
54. Hiremath, S.P.; Badami, S.; Hunasagatta, S.K.; Patil, S.B. Antifertility and hormonal properties of flavones of Striga orobanchioides. Eur. J. Pharmacol. 2000, 391, 193-197.
55. Xu, Y.C.; Leung, S.W.; Yeung, D.K.; Hu, L.H.; Chen, G.H.; Che, C.M.; Man, R.Y. Structure-activity relationships of flavonoids for vascular relaxation in porcine coronary artery. Phytochemistry 2007, 68, 1179-1188.